Tapestry Pharmaceuticals Inc.

Martin Batt has served as our Vice President, Chief Operating Officer since July 2004. Mr. Batt has also been Chief Information Officer since September 2002. Prior to joining us, from 1986 to August 2002, he was a Partner in the consulting firm of Grisanti, Galef & Goldress which specializes in operating and fixing distressed companies by providing leadership in senior executive positions. Mr. Batt has assumed various positions including CEO, President and Vice President in many industries including retailing, aerospace, communications, computer software, steel, computer hardware, carpet, apparel, and automotive parts manufacturing. Prior to that, Mr. Batt served in various Information Technology positions at U. S. Steel Corporation. Mr. Batt received a B.S. in Computer Sciences, Cum Laude, from Point Park College, Pittsburgh and has also taught Computer Science and Information Technology.

Elliot M. Maza, age 51, has served as a member of our Board of Directors since December 2004. Since May 2006, Mr. Maza has served as President and Chief Financial Officer of Intellect Neurosciences, Inc., a biopharmaceutical company specializing in the research and development of drugs to treat Alzheimer s disease and other major disorders of the central nervous system. From December 2003 to May 2006, Mr. Maza was Chief Financial Officer of Emisphere Technologies, Inc., a public biopharmaceutical company specializing in oral drug delivery. From March 1999 to December 2003, he was a partner at Ernst & Young LLP. Prior to that, Mr. Maza held various positions at Goldman Sachs & Co., J.P. Morgan Securities, Inc. and the law firm of Sullivan & Cromwell LLP. He is a certified public accountant. Mr. Maza received a B.A. in accounting from Touro College and a J.D. from the University of Pennsylvania Law School.

Stephen K. Carter, M.D. has served on our Board of Directors since September 1998. Since 1997, Dr. Carter has been a consultant to the pharmaceutical industry. Dr. Carter was Senior Vice President of Research and Development at Boehringer Ingelheim Pharmaceuticals, Inc. from 1995 to 1997. Prior to joining Boehringer, Dr. Carter was Senior Vice President of Worldwide Clinical Research and Development at Bristol-Myers Squibb Company. From 1976 to 1982, Dr. Carter served as Director of the Northern California Cancer Program. Dr. Carter was also appointed to President Clinton's panel for AIDS drug development. Dr. Carter is a director of Allos Therapeutics, Alfacell Corporation, Emisphere Technologies, Inc. and Vion Pharmaceuticals Inc. and several privately held companies. Dr. Carter received an A.B. in History from Columbia College and an M.D. degree from New York Medical College. He completed a medical internship and residency at Lenox Hill Hospital.

Dr. Rowinsky is the Director of the Institute for Drug Development, Cancer Therapy and Research Center and Chief Medical Officer of Imclone, Inc. He serves as the Editor-in-Chief of Investigational New Drugs and as an Associate Editor for various publications, including Cancer Research. Dr. Rowinsky also serves on the NCI Board of Scientific Counselors. He is actively involved in preclinical and clinical research in anticancer drug development and has played pivotal roles in the regulatory approval of a large number of contemporary anticancer therapeutics such as Taxotere . Dr. Rowinsky received his M.D. from the Vanderbilt School of Medicine.

Dr. Pollack grew up in Brooklyn, attended public schools, and graduated from Columbia College with a major in physics in 1961. He holds a Ph.D. in biology from Brandeis University. He is Professor of Biological Sciences, Lecturer in Psychiatry at the Center for Psychoanalytic Training and Research, and Director of the Center for the Study of Science and Religion, at Columbia University since 1978, and was Dean of Columbia College from 1982 to 1989. He received the Alexander Hamilton Medal from Columbia University, and has held a Guggenheim Fellowship. Dr. Pollack is the author of more than a hundred research papers on the oncogenic phenotype of mammalian cells in culture, and has edited many books and reviews on aspects of molecular biology. Since 1994 Dr. Pollack has concentrated his efforts on questions that lie at the margin of science and religion. His latest work, "The Faith of Biology and the Biology of Faith: order, meaning and free will in modern science," was published in 2000, as the inaugural volume of a Columbia University Press series of books on Science and Religion. He is currently working on a book on childhood depression. Since 1998 Dr. Pollack has been the President of the Hillel of Columbia University and Barnard College, located in the new Robert K. Kraft Family Center for Jewish Student Life.

Dr. Eckhardt is a Professor of Medicine and the Director of the Developmental Therapeutics and GI Malignancies Programs at the University of Colorado Health Science Center in Denver. She is a member of the ASCO Board of Directors and ASCO Publications Committee. She previously worked as an Associate Director of Clinical Research, Cancer Therapy and Research Center at the Institute for Drug Development in San Antonio, Texas. Dr. Eckhardt received her M.D. from the University of Texas Medical Branch in Galveston.

Stephen K. Carter, M.D., a Director of the Company since 2003, is the former Senior Vice President, Clinical and Regulatory Affairs, of Sugen, Inc. (ownership of Sugen has since passed to Pfizer, Inc. as part of its acquisition of Pharmacia in April 2003). Dr. Carter previously was the Senior Vice President, Research and Development of Boehringer Ingelheim Pharmaceuticals, Inc., now independently owned. Prior to this, he served 13 years at Bristol-Myers Squibb Co., including, as its Senior Vice President, Worldwide Clinical Research and Development. Dr. Carter is a former Deputy Director at the National Cancer Institute (NCI)'s Division of Cancer Treatment and is a member of the American Society of Clinical Oncology. He received his Medical Doctorate from New York Medical College. He is currently a member of the boards of directors of Alfacell Corporation, Achillion Pharmaceuticals, Inc., Cytogen Corporation, Sopherion Therapeutics, Inc., and Vion Pharmaceuticals, Inc.

Dr. Susan Band Horwitz is a Distinguished University Professor and the Rose C. Falkenstein Professor of Cancer Research. She is Co-Chair of the Department of Molecular Pharmacology at the Albert Einstein College of Medicine and Associate Director for Therapeutics at the Albert Einstein Cancer Center. Dr. Horwitz has had a continuing interest in natural products as a source of new drugs for the treatment of cancer. Her laboratory has made Taxol, a drug isolated from the yew plant, Taxus brevifolia, a major focus of its work. Dr. Horwitz and her collaborators demonstrated that the effects of Taxol were due to a novel interaction between the drug and microtubules, the latter being essential for the pairing and segregation of chromosomes during cell division.